Adjuvant Therapy

Adjuvant S-1 therapy significantly extended survival compared with surgery alone among patients with resected biliary tract cancer, according to results of a study conducted in Japan and presented at ASCO Gastrointestinal Cancers Symposium.

Pembrolizumab extended DFS compared with placebo as adjuvant treatment for patients with stage IB to stage IIIA non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA expanded the approval of pembrolizumab to include adjuvant treatment of certain patients with renal cell carcinoma.

For years, adjuvant therapy for renal cell carcinoma was ‘under future direction’ in any research discussion.

The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.

The FDA granted priority review to pembrolizumab for adjuvant treatment of certain patients with high-risk melanoma.

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about data from the IMpower010 trial presented at the virtual ASCO Annual Meeting.

Pembrolizumab extended RFS compared with high-dose interferon or ipilimumab as adjuvant therapy for patients with high-risk melanoma, according to randomized phase 3 study results presented during the virtual ASCO Annual Meeting.

In this video exclusive, Roi Anteby, MD, postdoctoral research fellow, department of surgery, Massachusetts General Hospital, discussed the affect of race, socioeconomic status and education on completion of adjuvant therapy for pancreatic cancer.

Atezolizumab after surgery and chemotherapy reduced risk for disease recurrence or death among patients with stage II to stage IIIA non-small cell lung cancer, according to research presented during the virtual ASCO Annual Meeting.